New Agents Topple Resistance in NSCLC

Dr. Mark Kris reports on new agents that overcome acquired resistance to EGFR TKIs in patients with NSCLC who have a T790 mutation, and recommends rebiopsying patients to identify who would benefit.
Source: Medscape Oncology - Category: Cancer & Oncology Authors: Source Type: podcasts